Connor Iapoce

An analysis at ADA 2023 presents novel findings on the inverse association between clinical and biochemical factors in diabetic retinopathy and age-related macular degeneration.

In an interview at ADA 2023, Aggarwal discusses the efficacy of sotagliflozin on heart failure-related outcomes independent of A1c and the greater implications of these findings.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.

New results from the ongoing clinical trial of VX-880 suggested all patients with T1D treated with the novel stem cell-derived islet cell therapy showed restored endogenous insulin secretion and improved glycemic control.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

A systematic review and meta-analysis found no significant differences in visual and anatomical outcomes between ranibizumab biosimilars and reference ranibizumab in eyes with neovascular AMD.

The new scientific statement from the AHA indicates multiple social, economic, and health variables contribute to disparities in the development, diagnosis, and treatment of PAD.

An analysis provided updated estimates of the US prevalence of DR and VTDR, showing that 9.6 million people had DR and 1.84 million people had VTDR in 2021.

The analysis of the DRCR Retina Network Protocol AC suggested cost savings occur with bevacizumab-first step therapy in eyes with DME, but the magnitude might not be as great as previously understood.

Additional phase 4 trial results presented at ENDO 2023 reinforce the efficacy and safety of teprotumumab-trbw in eyes with TED, regardless of disease activity or duration.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

The investigative team observed a U-shaped relationship between sleep duration and incident diabetes, with the greatest risk when sleep duration was ≥10 hours per day.

An analysis of US adults suggests MAFLD affects the Hispanic population at a higher prevalence relative to Black adults and White adults.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, to discuss the recent FDA approval of pegcetacoplan (SYFOVRE™), the interplay between being a clinician and corporate executive, and how the retina landscape may change in the coming years.

Among more than 80,000 older adults with T2D and established CVD, those in the highest quartile of out-of-pocket costs were less likely to initiate a GLP-1 R or SGLT2 inhibitor.

Intravitreal corticosteroid injections improved vision in eyes with persistent or recurrent uveitis-related macular edema better than methotrexate or ranibizumab injections.

An analysis of the Dubbo study suggests elevated Lp(a) is an independent and significant predictor of recurrent CHD in older people over a 16-year period.

At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.

An analysis suggests biosimilar bevacizumab was safe and effective over 6 weeks with noted improvement in BCVA and OCT parameters for patients with macular edema.

Cross-sectional findings from Hong Kong suggest exposure to secondhand smoke presented a dose-dependent association with myopia among children aged 6 to 8 years.

An analysis based in Japan suggests ranibizumab biosimilar is dominant to other anti-VEGF treatments in patients with nAMD in both treat-and-extend and PRN regimens.

The analysis of the XPLORE trial suggested XSB-001 showed biosimilarity to reference ranibizumab as assessed by BCVA improvement at 8 weeks.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

However, results from the Vet-COACH trial reported a significant improvement in mental health–related quality of life in the intervention group compared with the control group.

Improved symptoms in 3 men with heart failure caused by ATTR-CM were confirmed by cardiovascular magnetic resonance scans showing the build-up of amyloid proteins had cleared.